Abstract
While diet response prediction for cardiometabolic risk factors (CRFs) has been demonstrated using single SNPs and main-effect genetic risk scores, little investigation has gone into the development of genome-wide diet response scores. We sought to leverage the multi-study setup of the Women’s Health Initiative cohort to generate and test genetic scores for the response of six CRFs (body mass index, systolic blood pressure, LDL-cholesterol, HDL-cholesterol, triglycerides, and fasting glucose) to dietary fat. A genome-wide interaction study was undertaken for each CRF in women (n ∼ 10000) not participating in the Dietary Modification (DM) trial, which focused on the reduction of dietary fat. Genetic scores based on these analyses were developed using a pruning-and-thresholding approach and tested for the prediction of one-year CRF changes as well as long-term chronic disease development in DM trial participants (n ∼ 5000). One of these genetic scores, for LDL-cholesterol (LDL-C), predicted changes in the associated CRF. This 1760-variant score explained 3.4% of the variance in one-year LDL-C changes in the intervention arm, but was unassociated with changes in the control arm. In contrast, a main-effect genetic risk score for LDL-C was not useful for predicting dietary fat response. Further investigation of this score with respect to downstream disease outcomes revealed suggestive differential associations across DM trial arms, especially with respect to coronary heart disease and stroke subtypes. These results lay the foundation for the combination of many genome-wide gene-diet interactions for diet response prediction while highlighting the need for further research and larger samples in order to achieve robust biomarkers for use in personalized nutrition.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received for this research.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.